Photo of Chen Lin from dukecancerinstitute.org
May 29, 2024, 15:16
Chen Lin: Updated results from FELIX for obecabtagene autoleucel in B-ALL by Elias Jabbour et al
Chen Lin, Assistant Professor at Duke Cancer Institute, shared on X/Twitter:
“Updated results from FELIX for obecabtagene autoleucel in B-ALL ASCO Oral 6504:
12months EFS 43%
Only 17% went to allo
Loss of CART persistence = decreased outcomes.
If obe-cel can maintain durable response without allo, would be an impressive feat.”
Source: Chen Lin/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 18, 2024, 12:57
Nov 18, 2024, 12:54
Nov 18, 2024, 12:50
Nov 18, 2024, 12:20
Nov 18, 2024, 12:17
Nov 18, 2024, 12:13